EP4784121A1 - Pharmazeutische zusammensetzungen mit 5-methoxy-n,n-dimethyltryptamin (5-meo-dmt) - Google Patents
Pharmazeutische zusammensetzungen mit 5-methoxy-n,n-dimethyltryptamin (5-meo-dmt)Info
- Publication number
- EP4784121A1 EP4784121A1 EP24787545.3A EP24787545A EP4784121A1 EP 4784121 A1 EP4784121 A1 EP 4784121A1 EP 24787545 A EP24787545 A EP 24787545A EP 4784121 A1 EP4784121 A1 EP 4784121A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- dmt
- meo
- composition
- patient
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2314911.5A GB202314911D0 (en) | 2023-09-28 | 2023-09-28 | Dosing of 5-MeO-DMT |
| GBGB2403419.1A GB202403419D0 (en) | 2024-03-08 | 2024-03-08 | Dosing of 5-MeO-DMT |
| GBGB2403721.0A GB202403721D0 (en) | 2024-03-14 | 2024-03-14 | Dosing of 5-meo-dmt |
| GBGB2405965.1A GB202405965D0 (en) | 2024-04-29 | 2024-04-29 | Dosing of 5-meO-DMT |
| PCT/GB2024/052500 WO2025068714A1 (en) | 2023-09-28 | 2024-09-27 | Pharmaceutical compositions comprising 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP4784121A1 true EP4784121A1 (de) | 2026-08-05 |
Family
ID=93061712
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP24787545.3A Pending EP4784121A1 (de) | 2023-09-28 | 2024-09-27 | Pharmazeutische zusammensetzungen mit 5-methoxy-n,n-dimethyltryptamin (5-meo-dmt) |
Country Status (2)
| Country | Link |
|---|---|
| EP (1) | EP4784121A1 (de) |
| WO (1) | WO2025068714A1 (de) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL297861A (en) | 2020-05-08 | 2023-01-01 | Psilera Inc | Novel compositions of matter and pharmaceutical compositions |
| US11312684B1 (en) | 2021-02-10 | 2022-04-26 | Eleusis Therapeutics Us, Inc. | Pharmaceutically acceptable salts of psilocin and uses thereof |
| WO2026068953A1 (en) * | 2024-09-27 | 2026-04-02 | Beckley Psytech Limited | Methods and kits comprising 5-meo-dmt for use in treating depression |
| WO2026068950A1 (en) * | 2024-09-27 | 2026-04-02 | Beckley Psytech Limited | Pharmaceutical compositions of 5-meo-dmt for use in the treatment of alcohol use disorders |
| WO2026068951A1 (en) * | 2024-09-27 | 2026-04-02 | Beckley Psytech Limited | 5-methoxy-dmt for use in the treatment of depression |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3007992B1 (fr) | 2013-07-05 | 2018-01-26 | Aptar France Sas | Dispositif de distribution de produit fluide ou pulverulent. |
| HUE066828T2 (hu) * | 2019-02-22 | 2024-09-28 | Gh Res Ireland Limited | 5-Metoxi-N,N-Dimetiltriptamin (5-Meo-Dmt) súlyos depressziós rendellenesség kezelésére |
| FR3098407B1 (fr) | 2019-07-10 | 2024-12-13 | Aptar France Sas | Dispositif de distribution nasale de poudre |
| BR112022025306A2 (pt) * | 2020-06-12 | 2023-02-28 | Beckley Psytech Ltd | Composição compreendendo um sal benzoato de 5-metóxin, n-dimetiltriptamina |
| GB202008961D0 (en) * | 2020-06-12 | 2020-07-29 | Beckley Psytech Ltd | Pharmaceutical composition |
| FR3117046B1 (fr) | 2020-12-09 | 2023-02-10 | Aptar France Sas | Dispositif de distribution de doses de poudre |
| FR3119772B1 (fr) | 2021-02-15 | 2024-06-14 | Aptar France Sas | Tête de distribution pour dispositif de distribution nasale d’un produit fluide ou pulvérulent |
| FR3121047B1 (fr) | 2021-03-29 | 2023-07-14 | Aptar France Sas | Dispositif de distribution nasale de poudre |
| EP4159192A1 (de) * | 2021-09-30 | 2023-04-05 | Biomind Labs Inc | Nasenspray auf dimethyltriptaminbasis für die personalisierte behandlung von neurologischen und psychiatrischen störungen |
| GB202212116D0 (en) * | 2022-08-19 | 2022-10-05 | Beckley Psytech Ltd | Pharmaceutically acceptable salts and Compositions thereof |
| WO2024105379A1 (en) * | 2022-11-14 | 2024-05-23 | Beckley Psytech Limited | Formulations of 5-meo-dmt |
-
2024
- 2024-09-27 EP EP24787545.3A patent/EP4784121A1/de active Pending
- 2024-09-27 WO PCT/GB2024/052500 patent/WO2025068714A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2025068714A1 (en) | 2025-04-03 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20260326 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR |